{
  "id": 16071,
  "url": "https://www.scmp.com/business/banking-finance/article/3362817/chinese-biotech-giant-wuxi-apptec-sees-first-half-earnings-surge-amid-us-scrutiny",
  "title": "Chinese biotech giant WuXi AppTec sees first-half earnings surge amid US scrutiny",
  "summary": "WuXi AppTec, Asia’s largest provider of contract pharmaceutical research, posted net income that smashed market expectations in the first half of the year amid strong demand tied to weight-loss and diabetes drugs, as well as gains in its US business. Interim net profit attributable to the owners of the Shanghai-based drug contractor advanced 33.7 per cent to 11.08 billion yuan (US$1.64 billion) from a year earlier, surpassing a Bloomberg mean consensus estimate – drawn from a pool of 25 analysts",
  "authors": "Julie Zhang",
  "category": "news",
  "topics": "healthcare,biotech",
  "orgs": null,
  "regions": "china",
  "published_at": "2026-08-03T12:30:14.000Z",
  "fetched_at": "2026-08-04T05:10:21.797Z",
  "source_slug": "x-scmp-tech-hk-cn",
  "source_name": "SCMP Tech (HK/CN)",
  "source_homepage": "https://www.scmp.com/tech",
  "ethics_ai_record_url": "https://ethics.ai/record/16071",
  "original_url": "https://www.scmp.com/business/banking-finance/article/3362817/chinese-biotech-giant-wuxi-apptec-sees-first-half-earnings-surge-amid-us-scrutiny",
  "evidence_status": "source-only",
  "attribution": "via ethics.ai"
}